Epic Research Update : Glenmark Pharmaceuticals

Glenmark Pharmaceuticals through its Swiss subsidiary has received $5 million as milestone payment from Sanofi on a collaboration of its VLA2 (alpha2-beta l) integrin monoclonal antibody. GBR 500 is a first-in-class therapeutic monoclonal antibody for chronic autoimmune disorders.

For more information ✆ - 0731-6642300 or Visit https://www.epicresearch.co/